Hypersensitivity reactions to chemotherapeutic antineoplastic agents;Reazioni da ipersensibilità a chemioterapici antitumorali

Recenti Progressi in Medicina

Volumn 95, Issue 10, 2004, Pages 476-481

  Rossi, Francesco ^a   Incorvaia, Cristoforo ^b   Mauro, Marina ^c  

^a Ospedale Predabissi   (Italy)

^b PARKINSON INSTITUTE   (Italy)

^c SANT ANNA HOSPITAL   (Italy)

Author keywords

Chemotherapeutic antineoplastic drugs; Hypersensitivity reactions

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; ANTINEOPLASTIC ANTIMETABOLITE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CARBOPLATIN; CISPLATIN; OXALIPLATIN; PLATINUM COMPLEX;

ARTICLE; COMPARATIVE STUDY; DRUG HYPERSENSITIVITY; HUMAN; NOMENCLATURE;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARBOPLATIN; CISPLATIN; DRUG HYPERSENSITIVITY; HUMANS; ORGANOPLATINUM COMPOUNDS; TERMINOLOGY;

EID: 16544384005     PISSN: 00341193     EISSN: 20381840     Source Type: Journal    
DOI: 10.1701/44.396     Document Type: Review

References (58)

1. Bonadonna G, Robustelli della Cuna G, Valagussa P. Medicina oncologica. Milano: Masson 2003.
2. Shanholtz C. Acute life-threatening toxicity of cancer treatment. Crit Care Clin 2001; 17: 483-502.
3. Johansson SGO, Hourihane JO'B, Bousquet J. A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. Allergy 2001; 56: 813-24.
4. Botana LM, Arnaez E, Vieytes MR, et al. Non-immunological release of histamine from mast cells elicited by antineoplastic agents. Cancer Chemoter Pharmacol 1992; 29: 495-498.
5. Weiss RB, Bruno S. Hypersensitivity reactions to cancer chemotherapeutic agents. Ann Intern Med 1981; 94: 66-72.
6. Weiss RB. Hypersensitivity reactions. Semin Oncol 1992; 19: 458-77.
7. Aulbert E, Schmidt CG. Anaphylactic reaction in cyclophosphamide infusion. Onkologie 1983; 6: 82-3.
8. Minami R, Hirase N, Motomura S, et al. Anaphylactoid reaction to cyclophosphamide in a patient with T cell lymphoma and hemophagocytic syndrome. Int J Hematol 1999; 69: 57-8.
9. Torricelli R, Kurer SB, Kroner T, Wutrich B. Delayed allergic reaction to Chlorambucil (Leukeran). Case report and literature review. Schweiz Med Wochenschr 1995; 125: 1870-3.
10. Bryant R. Use of a protocol to minimize hypersensitivity reactions with asparaginase administration. J Intraven Nurs 2001; 24: 169-73.
11. Zanotti KM, Markman M. Prevention and management of antineoplastic- induced hypersensitivity reactions. Drug Saf 2001; 24: 767-79.
12. Larson RA, Fretzin MH, Dodge RK, Schiffer CA. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia. Leukemia 1998; 12: 660-5.
13. Alkins SA, Byrd JC, Morgan SK, et al. Anaphylactoid reactions to methotrexate. Cancer 1996; 77: 2123-6.
14. Ricci S, Antonuzzo A, Galli L, et al. Gemcitabicine monotherapy in elderly patients with advanced non-small cell lung cancer: a multicenter phase II study. Lung Cancer 2000; 27: 75-80.
15. Hoetelmans RM, Schornagel JH, ten Bokkel Huinink WW, Beijnen JH. Hypersensitivity reactions to etoposide. Ann Pharmacoter 1996; 30: 367-71.
16. Hudson MM, Weinstein HJ, Donaldson SS, et al. Acute hypersensitivity reactions to etoposide in a VEPA regimen for Hodgkin's disease. J Clin Oncol 1993; 11: 1080-4.
17. Siderov J, Prased P, De Boer R, Desai J. Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide. Br J Cancer 2002; 86: 12-3.
18. Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990; 8: 1263-8.
19. Peereboom DM, Donehower RC, Eisenhower EA, et al. Successful re-treatment with taxol after major hypersensitivity reactions. J Clin Oncol 1993; 11: 885-90.
20. Del Priore G, Smith P, Warshal DP, et al. Paclitaxel-associated hypersensitivity reactions despite highdose steroids and prolonged infusions. Gynecol Oncol 1995; 56 :316-8.
21. Kwon JS, Elit L, Finn M, et al. A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel. Gynecol Oncol 2002; 84: 420-5.
22. Markman M, Kennedy A, Webster K, et al. Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. J Clin Oncol 2000; 18: 102-5.
23. Cormio G, Di Vagno G, Melilli GA, et al. Hypersensitivity reactions in ovarian cancer patients receiving paclitaxel. J Chemoter 1999; 11: 407-9.
24. Cantu MG, Buda A, Parma G, et al. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol 2002; 20:1232-7.
25. Laohavinij S, Maoleekoonpairoj S, Cheirsilpa A, et al. Phase II study of paclitaxel and carboplatin for advanced non-small-cell lung cancer. Lung Cancer 1999; 26: 175-85.
26. Helsing M, Thaning L, Sederholm C, et al. Treatment with paclitaxel 1-h infusion and carboplatin of patients with advanced non-small-cell lung cancer: a phase II multicentre trial. Joint Lung Cancer Study Group. Lung Cancer 1999; 24: 107-13.
27. Grosen E, Siitari E, Larrison E, et al. Paclitaxel hypersensitivity reactions related to bee-sting allergy. Lancet 2000; 355: 288-9.
28. Kunitoh H, Watanabe K, Onoshi T, et al. Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study. J Clin Oncol 1996; 14: 1649-55.
29. Cardoso F, Ferreira Filho AF, Crown J, et al. Doxorubicin followed by docetaxel versus docetaxel followed by doxorubicin in the adjuvant treatment of node positive breast cancer: results of a feasibility study. Anticancer Res 2001; 21: 789-95.
30. Kornek GV, Haider K, Kwasny W, et al. Treatment of advanced breast cancer with docetaxel and gemcitabicine with and without human granulocyte colony-stimulating factor. Clin Cancer Res 2002; 8: 1051-6.
31. Georgoulias V, Androulakis N, Dimopoulos AM, et al. First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: a multicenter phase II study. Ann Oncol 1998; 9: 331-4.
32. Georgoulias V, Kouroussis C, Androulakis N, et al. Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabicine: a multicenter phase II trial. J Clin Oncol 1999; 17: 914-20.
33. Moon C, Verschraegen CV, Bevers M, et al. Use of docetaxel (Taxotere) in patients with paclitaxel (Taxol) hypersensitivity. Anticancer Drugs 2000; 11: 565-8.
34. Mackay HJ, McInnes A, Paul J, et al. A phase II study of epirubicin, cisplatin and raltitrexed combination chemotherapy (ECT) in patients with advanced oesophageal and gastric adenocarcinoma. Ann Oncol 2001; 12: 1407-10.
35. Lotem M, Hubert A, Lyass O, et al. Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol 2000; 136: 1475-80.
36. Khansur T, Little D, Tavassoli M. Fulminant and fatal angioedema caused by bleomycin treatment. Arch Intern Med 1984; 133: 2267.
37. Taylor WB, Cantwell BM, Roberts JT, Harris AL. Allergic reactions to mitoxantrone. Lancet 1986; 1: 1439.
38. Walusiak J, Wittczek T, Ruta V, et al. Occupational asthma due to mitoxantrone. Allergy 2002; 57: 461.
39. Robinson JB, Singh D, Bodurka-Bevers DC, et al. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies. Gynecol Oncol 2001; 82: 550-8.
40. Kim ES, Lu C, Khuri FR, et al. A phase II study of STEALTH cisplatin (SPI-77. in patients with advanced non-small-cell lung cancer. Lung Cancer 2001; 34: 427-32.
41. Glisson BS, Murphy BA, Frenette G, et al. Phase II trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. J Clin Oncol 2002; 20: 1593-9.
42. Zweizig S, Roman LD, Muderspach LI. Death from anaphylaxis to cisplatin: a case report. Gynecol Oncol 1994; 53: 121-2.
43. Dizon DS, Sabbatini PJ, Aghajanian C, et al. Analysis of patients with ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. Gynecol Oncol 2002; 84: 378-82.
44. Onoyama Y, Umezu T, Kuriaki Y, Honda N. Hypersensitivity reactions to cisplatin following multiple uncomplicated courses: a report on two cases. J Obstet Gynaecol Res 1997 ; 23: 347-52.
45. Hebert ME, Blivin JL, Kessler J, et al. Anaphylactoid reactions with intraperitoneal cisplatin. Ann Pharmacother 1995; 29: 260-3.
46. Denis L. Anaphylactic reactions to repeated intravesical instillation with cisplatin. Lancet 1983; 1: 1378-9.
47. Markman M, Kennedy A, Webster K, et al. Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 1999; 17: 1141-4.
48. Polyzos A, Tsavaris N, Kosmas C, et al. Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. Oncology 2001; 61: 129-33.
49. Pectasides D, Aspropotamidis A, Halikia A, et al. Combination chemotherapy with carboplatin, docetaxel, and gemcitabicine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 1999; 17: 3816-21.
50. Zanotti KM, Rybicki LA, Kennedy AW, et al. Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J Clin Oncol 2001; 19: 3126-9.
51. Kosmidis P, Mylonakis N, Fountzilas G, et al. Paclitaxel and carboplatin in nonoperable non-small-cell lung cancer. Semin Oncol 1996; 23: 16-8.
52. Shin DM, Glisson BS, Khuri FR, et al. Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. Cancer 2002; 95: 322-30.
53. Tournigand C, Maindrault-Goebel F, Louvet C, et al. Severe anaphylactic reactions to oxaliplatin. Eur J Cancer 1998 ; 34: 1297-8.
54. Meyer L, Zuberbier T, Worm M, et al. Hypersensitivity reactions to oxaliplatin: cross-reactivity to carboplatin and the introduction of a desensitization schedule. J Clin Oncol 2002; 20: 1146-7.
55. Kamm GL, Hagmeyer KO. Allergic-type reactions to corticosteroids. Ann Pharmacoter 1999; 33: 451-60.
56. Galindo PA, Borja J, Feo F. Fixed drug eruption caused by cyproterone acetate. Allergy 1998; 53: 813.
57. Akoun GM, Liote HA, Gauthier-Rahman S, Kuntz D. Provocation test coupled with bronchoalveolar lavage in diagnosis of drug (nilutamide)-induced hypersensitivity pneumonitis. Chest 1990; 97: 495-8.
58. Raj SG, Karadsheh AJ, Guillot RJ, Raj MH, Kumar P. Case report: systemic hypersensitivity reaction to goserelin acetate. Am J Med Sci 1996; 312: 187-90.